BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31765478)

  • 21. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.
    Szuber N; Vallapureddy RR; Penna D; Lasho TL; Finke C; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
    Am J Hematol; 2018 Dec; 93(12):1474-1484. PubMed ID: 30157297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.
    Barzilai M; Kirgner I; Avivi I; Ellis M; Dally N; Rozovski U; Lavi N
    Eur J Haematol; 2019 Jun; 102(6):504-508. PubMed ID: 30941804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map.
    Shallis RM; Wang R; Davidoff A; Ma X; Podoltsev NA; Zeidan AM
    Blood Rev; 2020 Jul; 42():100706. PubMed ID: 32517877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms.
    Zhang Y; Han Y; Teng G; Du C; Gao S; Yuan W; Zhang L; Bai J
    Cancer Med; 2023 Apr; 12(8):9236-9246. PubMed ID: 36727544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
    Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
    Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.
    Engle EK; Fisher DA; Miller CA; McLellan MD; Fulton RS; Moore DM; Wilson RK; Ley TJ; Oh ST
    Leukemia; 2015 Apr; 29(4):869-76. PubMed ID: 25252869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study.
    Hur JY; Choi N; Choi JH; Kim J; Won YW
    Thromb Res; 2024 Apr; 236():209-219. PubMed ID: 38461615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.
    Frederiksen H; Farkas DK; Christiansen CF; Hasselbalch HC; Sørensen HT
    Blood; 2011 Dec; 118(25):6515-20. PubMed ID: 22039256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Takagi S; Masuoka K; Uchida N; Kurokawa M; Nakamae H; Imada K; Iwato K; Ichinohe T; Atsuta Y; Takami A; Yano S
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2208-2213. PubMed ID: 27667010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Andıç N; Ünübol M; Yağcı E; Akay OM; Yavaşoğlu İ; Kadıköylü VG; Bolaman AZ
    Turk J Haematol; 2016 Sep; 33(3):187-95. PubMed ID: 27094255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
    Rampal R; Mascarenhas J
    Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
    Mora B; Rumi E; Guglielmelli P; Barraco D; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Cavalloni C; Pietra D; Barbui T; Rotunno G; Cazzola M; Vannucchi AM; Giorgino T; Passamonti F
    Cancer Med; 2019 Aug; 8(9):4089-4092. PubMed ID: 31173472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
    Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis.
    Cottin L; Riou J; Boyer F; Bouvier A; Zannetti A; Blouet A; Truchan-Graczyk M; Jouanneau-Courville R; Beucher A; Ribourtout B; Orvain C; Hunault-Berger M; Blanchet O; Ugo V; Luque Paz D
    Blood Cells Mol Dis; 2019 Mar; 75():35-40. PubMed ID: 30612065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloproliferative and lymphoproliferative disorders: State of the art.
    Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
    Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.
    Yang N; Park S; Cho MS; Lee M; Hong KS; Mun YC; Seong CM; Huh HJ; Huh J
    Ann Lab Med; 2018 Jul; 38(4):296-305. PubMed ID: 29611379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
    Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
    BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know?
    Cuthbert D; Stein BL
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):65-73. PubMed ID: 30927977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.